Neurocrine Biosciences, Inc. (NBIX)
Morgan Stanley Global Healthcare Conference Call
September 12, 2012 08:00 AM ET
Kevin C. Gorman - President, CEO
It is my pleasure to introduce Kevin Gorman, President and CEO of Neurocrine Biosciences. And I think just to start, if you can give us a brief overview of what you guys have going on currently?
Kevin C. Gorman
Sure, [Sarah]. Thank you very much and thank you to Morgan Stanley for the opportunity to come today and speak. I will be making forward-looking statements throughout this Q&A. So, I would like you to – direct you to our recent SEC filings for all the risk factors associated with that. Neurocrine Biosciences is a neuroendocrine Company. We have two main programs that are going on in the Company today and I think that most of our questions are going to center around that and I do look forward to taking any questions that you all might have. The first program is our GnRH program. The lead compound is called Elagolix. It’s partnered with Abbott Pharmaceuticals. Abbott has the drug in the Phase 3 trial for endometriosis and they have it in a Phase 2 proof-of-concept trial ongoing in uterine fibroids.
This is a program that was discovered at Neurocrine approximately 11 years ago and we formed a relationship with Abbott approximately 2.5 years ago. The second program which was wholly owned by Neurocrine and again completely all the discovery was done at Neurocrine starting about five years ago is a VMAT2 inhibitor. VMAT2 is a presynaptic target, Vesicular Mono-Amine Transporter and we have this – currently we’re going to be starting Phase 2b study in Tardive Dyskinesia and Tardive Dyskinesia is a movement disorder that is caused by antipsychotic drugs.
Check Out Our Best Services for Investors
Jim Cramer and Stephanie Link reveal their investment tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
Jim Cramer's protégé, David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts